SwanBio Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.swanbiotx.com
Clinical Trials
2
Active:2
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
Phase 1
Active, not recruiting
- Conditions
- X-ALDAMN Gene MutationAMN
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- SwanBio Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05394064
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
🇳🇱Amsterdam UMC, Amsterdam, Netherlands
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia
Active, not recruiting
- Conditions
- AMN Gene MutationAMNX-ALD
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- SwanBio Therapeutics, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT05008874
- Locations
- 🇺🇸
Stanford Neuroscience Health Center, Stanford, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
News
No news found